{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T05:11:07Z","timestamp":1698383467934},"reference-count":8,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2006,6,30]],"date-time":"2006-06-30T00:00:00Z","timestamp":1151625600000},"content-version":"vor","delay-in-days":4198,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pacing Clinical Electrophis"],"published-print":{"date-parts":[[1995,1]]},"abstract":"<jats:p>To investigate the impact of staged therapy for advanced heart failure on therapeutic endpoints, 236 consecutive patients (coronary artery disease\/dilated cardiomyopathy in 61\/175 patients, left ventricular ejection fraction 14%\u00b1 5%, New York Heart Association Class IIl\/IIIIV in 102\/79\/55 patients, respectively) with advanced heart failure were prospectively followed. One hundred thirtyseven patients enrolled from January 1989 to December 1991 were treated conventionally with digoxin, furosemide, and low dose angiotension converting enzyme (ACE) inhibition. Patients refractory to this therapy underwent urgent heart transplantation. Ninetynine patients enrolled from January 1992 to August 1993 underwent staged therapy: stage 1: maximal tolerated ACE inhibition; stage 2: therapy with PGE<jats:sub>1<\/jats:sub> for preand afterload reduction to achieve hemodynamic stabilization; or stage 3: refractory patients bridged to heart transplantation with continuous outpatient dobutamine. Sudden death was defined as death within 1 hour of symptoms if heart failure symptoms remained stable over the previous 7 days. Conventionally treated patients were followed for 10 \u00b1 9 months; patients who underwent staged therapy for 9 \u00b15 months. In the group of patients that underwent standard therapy, 39 of 137 (28%) patients died: 5 (13%) deaths occurred suddenly, and death due to progressive pump failure occurred in the remaining 34 (87%) patients. In the group of patients that underwent staged therapy, 25 of 99 (25%) patients died: 13 (52%) deaths occurred suddenly, and 12 (48%) deaths occurred due to progressive pump failure. Thus, patients who underwent staged therapy were at increased risk for sudden death (P = 0.01, relative risk 3.4, 95% confidence interval 1.2\u20139.7) but were at lower risk for death from pump failure (P = 0.009, relative risk 0.44, 95% confidence interval 0.22\u20130.84). In patients who underwent therapy with continuous outpatient PGE<jats:sub>1<\/jats:sub> (n = 7) or dobutamine (n= 21), risk for sudden death (P = NS by log rank test) did not increase. In conclusion, staged therapy significantly reduced death from pump failure; however, patients who could be stabilized and considered too well for heart transplantation were at increased risk for sudden death. Thus, overall survival did not improve. Of note, outpatient dobutamine did not increase the risk for sudden death.<\/jats:p>","DOI":"10.1111\/j.1540-8159.1995.tb02495.x","type":"journal-article","created":{"date-parts":[[2006,7,2]],"date-time":"2006-07-02T15:57:30Z","timestamp":1151855850000},"page":"152-158","source":"Crossref","is-referenced-by-count":3,"title":["Sudden Death and Staged Therapy for Hemodynamic Stabilization in Patients Enrolled in a Heart Transplantation Program"],"prefix":"10.1111","volume":"18","author":[{"given":"BERNHARD","family":"FREY","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MICHAEL","family":"WUTTE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RUDOLF","family":"BERGER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"CLEANTHIS","family":"IOANNIDES","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MARTIN","family":"H\u00dcLSMANN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"BRIGITTE","family":"STANEK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"RICHARD","family":"PACKER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,6,30]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"I28","article-title":"Management of the patient awaiting cardiac transplantation","volume":"15","author":"Mills RM.","year":"1992","journal-title":"Clin Cardiol"},{"key":"e_1_2_1_3_2","first-page":"86","article-title":"Cardiac transplantation at Stanford","volume":"1","author":"Jamieson SW","year":"1982","journal-title":"J Heart Transplant"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.74.6.1303"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(89)90320-2"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1540-8159.1992.tb05167.x"},{"key":"e_1_2_1_7_2","first-page":"VI24","article-title":"for the V\u2010 HeFT VA Cooperative Studies Group","volume":"87","author":"Goldman S","year":"1993","journal-title":"Mechanism of death in heart failure. The vasodilator-heart failure trials. Circulation"},{"key":"e_1_2_1_8_2","first-page":"249","article-title":"Registry of the International Society for Heart Transplantation: Fifth official report","volume":"7","author":"Solis E","year":"1988","journal-title":"J Heart Transplant"},{"key":"e_1_2_1_9_2","first-page":"267","article-title":"Urgent priority transplantation: When should it be done","volume":"6","author":"Stevenson LW","year":"1987","journal-title":"J Heart Transplant"}],"container-title":["Pacing and Clinical Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1540-8159.1995.tb02495.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1540-8159.1995.tb02495.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,27]],"date-time":"2023-10-27T00:31:07Z","timestamp":1698366667000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1540-8159.1995.tb02495.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1995,1]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1995,1]]}},"alternative-id":["10.1111\/j.1540-8159.1995.tb02495.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1540-8159.1995.tb02495.x","archive":["Portico"],"relation":{},"ISSN":["0147-8389","1540-8159"],"issn-type":[{"value":"0147-8389","type":"print"},{"value":"1540-8159","type":"electronic"}],"subject":[],"published":{"date-parts":[[1995,1]]}}}